Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose to Present at September Investor Conferences

Sep 09, 2020 7:30am EDT

Aptose Biosciences to Present at Canaccord Genuity 40th Annual Growth Conference

Aug 06, 2020 7:30am EDT

Aptose Reports Results for the Second Quarter 2020

Aug 04, 2020 4:01pm EDT

Aptose to Release Second Quarter Ended June 30, 2020 Financial ResultsĀ and Hold Conference Call on August 4, 2020

Jul 21, 2020 4:01pm EDT

Aptose Announces Pricing of Public Offering of Common Shares

Jul 15, 2020 10:49pm EDT

Aptose Announces Proposed Public Offering of Common Shares

Jul 15, 2020 4:01pm EDT

Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia

Jun 29, 2020 7:01am EDT

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Jun 12, 2020 7:00am EDT

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Jun 02, 2020 5:49pm EDT

Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

May 14, 2020 9:00am EDT
RSS
  • Prev
    • 1...
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • ...32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences